Drug intelligence / Profile preview

6-prenylnaringenin

Development stage
Preclinical
Lead developer
University Hospital Tübingen
Modality
Small Molecules
Administration
Oral
01

Overview

6-Prenylnaringenin (6-PN) is a naturally occurring prenylated flavonoid found primarily in hops (*Humulus lupulus*) and beer. It is an isomer of the potent phytoestrogen 8-prenylnaringenin (8-PN). Unlike 8-PN, 6-prenylnaringenin exhibits very weak estrogenic activity, making it an attractive candidate for non-hormonal therapeutic applications. It acts as a potent and reversible blocker of T-type voltage-gated calcium channels (specifically Cav3.2), a positive allosteric modulator of GABAA receptors, and an agonist of the aryl hydrocarbon receptor (AhR). Research has demonstrated its potential in alleviating neuropathic and visceral pain, inhibiting histone deacetylases (HDACs) to exert antiproliferative effects against various cancer cell lines (such as melanoma and prostate cancer), and promoting estrogen detoxification by inducing CYP1A1 expression. Clinical evaluation has focused on its safety, pharmacokinetics, and bioavailability, including the use of micellar solubilization to enhance its oral absorption.

Other names
(2R/S)-6-prenylnaringenin(2S)-6-prenylnaringenin(±)-6-prenylnaringenin6-PN6-prenyl naringenin
02

Targets

AHR (Aryl hydrocarbon receptor)CYP1A1 (Cytochrome P450 1A1)ESR1 (ERα)GABRR (GABA-A receptor subunit rho)HDAC (HDAC family)CACNA1H (T-type voltage-gated calcium channel 3.2)

Beyond the preview

Go deeper on 6-prenylnaringenin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 6-prenylnaringenin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call